MEK

Mitogen-activated protein kinase kinase; MAPKK; MAP2K

MEK

MEK Isoform Specific Products:

MEK Isoform Comparison

MEK Related Products (144)
Antibodies (9)
MEK Isoform Comparison

By Effects:	Inhibitors (130) Degrader (1) Antagonists (2) Activators (3)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-114323

PROTAC FLT-3 degrader 1	Inhibitor	99.74%
PROTAC FLT-3 degrader 1 is an effective and selective FLT-3 PROTAC degrader with an IC₅₀ of 0.6 nM. PROTAC FLT-3 degrader 1 inhibits both FLT-3 and FLT-3 ITD mutants. PROTAC FLT-3 degrader 1 has the activity of anti-proliferation and induction of apoptosis, which can be used in the study of tumor. (Pink: FLT3 ligand (HY-168702); Black: Linker (HY-124380); Blue: VHL ligand (HY-125845)).

HY-B0185B

Lidocaine hydrochloride hydrate	Inhibitor	99.90%
Lidocaine (Lignocaine) hydrochloride hydrate inhibits sodium channels involving complex voltage and using dependence. Lidocaine hydrochloride hydrate decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride hydrate is an amide derivative and has potential for the research of ventricular arrhythmia.

HY-107621

U0124		≥98.0%
U0124, an inactive U0126 analog, has no effect on c-Fos and c-Jun protein or mRNA levels. U0126 is a MEK inhibitor. U0124 does not inhibit MEK at concentrations up to 100 μM.

HY-13079

Cobimetinib (R-enantiomer)	Inhibitor	99.78%
Cobimetinib R-enantiomer is the less active R-enantiomer of Cobimetinib. Cobimetinib is a potent and selective MEK inhibitor.

HY-10254G

Mirdametinib (GMP)	Inhibitor
Mirdametinib (PD0325901) (GMP) is Mirdametinib (HY-10254) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mirdametinib is an orally active, selective and non-ATP-competitive MEK inhibitor.

HY-153445

MEK-IN-6	Inhibitor	98.69%
MEK-IN-6 (Example 69) is a MEK inhibitor. MEK-IN-6 inhibits ERK1/2 (Thr202/Tyr204) phosphorylation in A375 cells (IC₅₀: 2 nM). MEK-IN-6 can be used for research of cancer.

HY-131295

PD0325901-O-C2-dioxolane	Inhibitor	98.62%
PD0325901-O-C2-dioxolane has main portion of MEK inhibitor PD0325901. PD0325901-O-C2-dioxolane and a ligand of VHL or CRBN E3 ligase can be used in the synthesis of MEK1/2 degrader.

HY-142042

3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles	Inhibitor	99.84%
3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles is an inhibitor for bone morphogenetic protein 2 (BMP2) with an IC₅₀ of 2.2 μM. 3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles is inhibitor for mitogen-activated protein kinase 1 (MEK1). 3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles exhibits anti-inflammatory and neuroprotective activity in EAE mouse model.

HY-B0185AS

Lidocaine-d₁₀ hydrochloride	Inhibitor	99.79%
Lidocaine-d₁₀ (hydrochloride) is the deuterium labeled Lidocaine hydrochloride. Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride, an amide derivative, has the potential for the research of the ventricular arrhythmia[2].

HY-107619

PD-334581	Inhibitor	99.72%
PD-334581 is a MEK1 inhibitor.

HY-159846

Luvometinib	Inhibitor
Luvometinib is a mitogen-activated protein kinase (MEK) inhibitor with antitumor activity.

HY-107417

Hypothemycin	Inhibitor	≥98.0%
Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for VEGFR2/VEGFR1, MEK1/MEK2, FLT-3, PDGFRβ/PDGFRα, and ERK1/ERK2, respectively.

HY-10999R

Trametinib (Standard)	Inhibitor
Trametinib (Standard) is the analytical standard of Trametinib. This product is intended for research and analytical applications. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC₅₀s of about 2 nM. Trametinib activates autophagy and induces apoptosis.

HY-15496

E6201	Inhibitor
E6201 (ER-806201) is an ATP-competitive dual kinase inhibitor of MEK1 and FLT3. E6201 inhibits MEK1- induced ERK2 phosphorylation with an IC₅₀ value of 5.2 nM, MKK4-induced JNK phosphorylation with an IC₅₀ value of 91 nM, and MKK6-induced p38 MAPK phosphorylation with an IC₅₀ value of 19 nM. Anti-tumor and anti-psoriasis efficacy.

HY-B0185S1

Lidocaine-d₁₀	Inhibitor	98.89%
Lidocaine-d₁₀ is the deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia[2].

HY-10216

Refametinib (R enantiomer)	Inhibitor
Refametinib R enantiomer is a MEK inhibitor extracted from patent WO2007014011A2, compound 1022, has an EC₅₀ of 2.0-15 nM.

HY-14947

Balamapimod	Inhibitor	99.47%
Balamapimod (MKI 833) is a reversible Ras/Raf/MEK inhibitor with potential anti-tumor activity.

HY-N0811

Anemarsaponin B	Inhibitor
Anemarsaponin B is a steroidal saponin. Anemarsaponin B decreases the protein and mRNA levels of iNOS and COX-2. Anemarsaponin B reduces the expressions and productions of pro-inflammatory cytokines, including TNF-a and IL-6. Anemarsaponin B inhibits the nuclear translocation of the p65 subunit of NF-κB by blocking the phosphorylation of IκBα. Anemarsaponin B also inhibits the phosphorylation of MAP kinase kinases 3/6 (MKK3/6) and mixed lineage kinase 3 (MLK3). Anti-inflammatory effect .

HY-160414

TRX-COBI	Inhibitor
TRX-COBI ((R,R)-TRX-COBI; Trx-cobimetinib) is a MEK inhibitor targeting TRX fragments based on Fe²⁺. TRX-COBI has antitumor activity.

HY-139638

MEK4 inhibitor-1	Inhibitor	98.89%
MEK4 inhibitor-1 is a novel MEK4 inhibitor against pancreatic adenocarcinoma with an IC₅₀ value of 61 nM.

Trametinib	MEK1, IC₅₀: 2 nM	MEK2, IC₅₀: 2 nM			99.96%
Mirdametinib	MEK1, Ki: 1 nM	MEK2, Ki: 1 nM		MEK, IC₅₀: 0.33 nM	99.95%
PD98059	MEK1, IC₅₀: 2-7 μM	MEK2, IC₅₀: 50 μM			99.96%
U0126	MEK1, IC₅₀: 70 nM	MEK2, IC₅₀: 60 nM			98.45%
Selumetinib	MEK1, IC₅₀: 14 nM			MEK, IC₅₀: 12 nM	99.87%
TERT activator-1	MEK1	MEK2			99.50%
U0126-EtOH	MEK1, IC₅₀: 70 nM	MEK2, IC₅₀: 60 nM			99.41%
Cobimetinib	MEK1, IC₅₀: 4.2 nM				99.81%
Binimetinib				MEK, IC₅₀: 12 nM	99.28%
C16-PAF				MEK	99.85%
Isorhamnetin	MEK1				99.94%
Avutometinib				MEK, IC₅₀: 160 nM	99.02%
Lidocaine				MEK	99.96%
Trametinib (DMSO solvate)	MEK1, IC₅₀: 2 nM	MEK2, IC₅₀: 2 nM			99.56%
trans-Zeatin				MEK	99.83%
CI-1040	MEK1, IC₅₀: 17 nM				99.91%
Pimasertib	MEK1	MEK2			99.88%
Lixisenatide	MEK1	MEK2			99.93%
GDC-0623	MEK1, Ki: 0.13 nM (+ATP)				98.74%
Lidocaine hydrochloride				MEK	99.84%
BIX02189			MEK5, IC₅₀: 1.5 nM		99.99%
Trametiglue	MEK1	MEK2			98.81%
Refametinib	MEK1, IC₅₀: 19 nM	MEK2, IC₅₀: 47 nM			99.82%
TAK-733				MEK, IC₅₀: 3.2 nM	98.31%
APS-2-79	MEK1				99.38%
AZD8330	MEK1, IC₅₀: 7 nM	MEK2, IC₅₀: 7 nM			99.14%
Lidocaine (Standard)				MEK	99.85%
SL327	MEK1, IC₅₀: 180 nM	MEK2, IC₅₀: 220 nM			99.57%
MS432	MEK1, DC₅₀: 31 nM (in HT29 cells) MEK1, DC₅₀: 31 nM (in SK-MEL-28 cells)	MEK2, DC₅₀: 17 nM (in HT29 cells) MEK2, DC₅₀: 9.3 nM (in SK-MEL-28 cells)			99.78%
RGB-286638	MEK1, IC₅₀: 54 nM				99.70%
Azelnidipine	MEK1	MEK2			99.66%
MAP855	MEK1, IC₅₀: 3 nM				98.48%
BI-847325		MEK2, IC₅₀: 4 nM			98.15%
RO4987655	MEK1, IC₅₀: 5.2 nM	MEK2, IC₅₀: 5.2 nM			99.21%
Tunlametinib	MEK1	MEK2			98.25%
BIX02188			MEK5, IC₅₀: 4.3 nM		99.85%
GW284543			MEK5		99.94%
Zapnometinib				MEK, IC₅₀: 5.7 nM	99.85%
PD318088	MEK1	MEK2			99.91%
Cobimetinib hemifumarate	MEK1, IC₅₀: 4.2 nM				99.73%
RGB-286638 free base	MEK1, IC₅₀: 54 nM				98.07%
PD 198306				MEK	99.75%
Nedometinib	MEK1, IC₅₀: 135 nM				98.25%
MEK inhibitor				MEK	98.35%
PD184161				MEK, IC₅₀: 10-100 nM	98.08%
Lidocaine hydrochloride hydrate				MEK	99.90%
MEK-IN-6				MEK	98.69%
PD0325901-O-C2-dioxolane	MEK1	MEK2			98.62%
PD-334581	MEK1				99.72%
Hypothemycin	MEK1, Ki: 17 nM	MEK2, Ki: 38 nM			≥98.0%
E6201	MEK1, IC₅₀: 5.2 nM
Refametinib (R enantiomer)				MEK, EC₅₀: 2-15 nM
Balamapimod				MEK	99.47%
CHMFL-EGFR-202	MEK1, IC₅₀: 161 nM				99.75%
APS-2-79 hydrochloride	MEK1
GW284543 hydrochloride			MEK5
MEK/RAF-IN-1	MEK1, IC₅₀: 28 nM
MEK/PI3K-IN-2	MEK1, IC₅₀: 352 ± 2 nM
MEK/PI3K-IN-1	MEK1, IC₅₀: 124 ± 11 nM
Isorhamnetin (Standard)	MEK1
MEK1-IN-1	MEK1, : 10.29 nM
MEK-IN-6 hydrate				MEK
MEK-IN-1				MEK

Name
Email *

	Sorry, but the email address you supplied was invalid.

MEK

MEK

MEK Isoform Specific Products:

MEK Isoform Specific Products:

MEK Related Products (144)

Antibodies (9)

MEK Isoform Comparison

MEK Related Products (144):